Pathos AI raises $237M led by Bristol Myers Squibb, partners on Alzheimer's drug development
AI drug development company Pathos AI announced a $237 million Series E funding round led by Bristol Myers Squibb, reaching a $3 billion valuation. The deal includes a collaboration between Pathos AI, Bristol Myers Squibb, and Tempus AI to develop artificial intelligence tools for drug development in Alzheimer's disease and other neurological disorders.
